Thompson Siegel & Walmsley’s Avadel Pharmaceuticals AVDL Stock Holding History

Thompson Siegel & Walmsley’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-51,550	Closed	-$629K	–	695
2015 Q4	$629K	Buy	51,550 +17,300	+51%	+$270K	0.01%	305
2015 Q3	$559K	Buy	34,250 +27,450	+404%	+$605K	0.01%	319
2015 Q2	$144K	Buy	+6,800	New	+$122K	﹤0.01%	398
2015 Q1	–	Sell	-16,091	Closed	-$276K	–	691
2014 Q4	$276K	Sell	16,091 -33,409	-67%	-$477K	0.01%	371
2014 Q3	$708K	Sell	49,500 -2,200	-4%	-$31.6K	0.01%	295
2014 Q2	$776K	Buy	51,700 +39,300	+317%	+$474K	0.02%	297
2014 Q1	$166K	Buy	+12,400	New	+$133K	﹤0.01%	395

Other funds holding AVDL

Broadfin Capital New York $403M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

J. Goldman & Co New York $2.16B AUM 33.8% 1-Year Est. Return

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return